Short answer
Aardvark Therapeutics, Inc. (AARD) filed its Q3 2026 10-Q quarterly report on Nov 13, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$19M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$19M
- −17.6% YoY · −33.4% QoQ
- EPS (diluted)
- −$0.87
- −14.5% YoY · −31.8% QoQ
Source: XBRL data from the Aardvark Therapeutics, Inc. (AARD) Q3 2026 10-Q on SEC EDGAR. USD.
Aardvark Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no products approved for sale
- Net loss $19.2M vs $16.3M YoY, operating loss $19.7M vs $17.7M
- R&D expense $15.7M vs $13.7M, worst-performing line, driven by cardiac safety studies
- Cash, equivalents and short-term investments $60.3M at September 30, 2026, funding projected through 2027
- FDA clinical hold lifted in October 2026, ARD-201 development paused, FDA meeting scheduled for first quarter 2027
Risk Factors
- New regulatory risk triggered by October 2026 FDA clinical-hold lifting: no alignment yet on ARD-101 Phase 3 design, dose, or additional studies
- Most material update: cardiac safety findings led to HERO and OLE termination after 67 participants, despite FDA attribution of serious event to pitolisant interaction
- Near-term clinical risk: exploratory HERO and OLE data may not support future development, with HERO terminated before planned 90 participants
- Financial risk: $60.3 million cash, cash equivalents and short-term investments expected to fund operations through 2027, but new Phase 3 requires additional funding
- Market risk: PWS’s limited patient pool may delay enrollment, especially after prior clinical pauses and ARD-101 clinical hold
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aardvark Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.